Skip to Content

  • Search

View Additional Section Content

GOG-250 - A RANDOMIZED PHASE III EVALUATION OF DOCETAXEL (NSC #628503) AND GEMCITABINE (NSC #613327) PLUS G-CSF WITH BEVACIZUMAB (NSC #704865, IND #7921) VERSUS DOCETAXEL (NSC #628503) AND GEMCITABINE (NSC #613327) PLUS G-CSF WITH PLACEBO IN THE TREATMENT OF RECURRENT OR ADVANCED LEIOMYOSARCOMA OF THE UTERUS. NCI SUPPLIED AGENT: BEVACIZUMAB (NSC #704865, IND #7921)

Clinical Trial Categories

  • Corpus Uterus/Sarcoma Cancer
Contact
Hanjani Institute for Gynecologic Oncology at 215-885-0220

Location

  • Hanjani Institute for Gynecologic Oncology
    The Rosenfeld Cancer Center
    1200 Old York Rd, AMH - 1 Widener
    Abington, PA 19001
    Office: 215-885-0220
    Fax: 215-576-0740

Find a Physician
Search Our Directory

215-481-MEDI

Schedule a Test
Request an Appointment

215-481-EXAM

Clinical Trials Details